Catalyst Pharmaceuticals
Jacqueline Gatto, CPA has a diverse work experience in the field of taxation. Jacqueline started their career at RSM US LLP as an Associate in Taxation in January 2016 and was promoted to Senior Associate in August 2017. In August 2019, they became a Regional Supervisor specializing in Tax Services. After working at RSM US LLP for a total of five years, they joined Catalyst Pharmaceuticals, Inc. as a Tax Manager in March 2021. Currently, they hold the position of Tax Director, starting from January 2024.
Jacqueline Gatto, CPA pursued a Bachelor's degree in Accounting from Florida Atlantic University from 2011 to 2013. Jacqueline furthered their education at the same institution and obtained a Master's degree in Accounting from 2014 to 2015.
Catalyst Pharmaceuticals
2 followers
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.